Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Paragon 28, Inc. (NYSE: FNA) is a medical device company based in Englewood, Colorado and exclusively focused on the foot and ankle orthopedic market. This news page aggregates coverage related to the company’s specialized implants, instrumentation and digital tools for foot and ankle surgery, as well as key corporate and regulatory developments.
Readers can find updates on Paragon 28’s participation in major professional meetings such as the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference and the American Academy of Orthopaedic Surgeons (AAOS) Annual Conference. News from these events often highlights recently launched products, including systems for total ankle replacement, fibula fracture stabilization, syndesmotic repair, minimally invasive bunion correction and single-use power systems for foot and ankle procedures.
Coverage also includes announcements about Paragon 28’s digital initiatives, such as the SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠, a platform described as integrating AI, data analytics and 3D modeling to streamline surgical planning and execution. Corporate news items may address preliminary revenue updates, conference presentations, board appointments and legal or shareholder-related matters.
In addition, this page features transaction-related news, including the definitive agreement for Zimmer Biomet Holdings, Inc. to acquire Paragon 28 and subsequent regulatory milestones like the expiration of the Hart-Scott-Rodino Act waiting period. By reviewing these articles, investors and observers can follow how Paragon 28’s product launches, strategic initiatives and proposed corporate transactions shape its role in the foot and ankle orthopedic segment over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on May 10, 2023, at 5:20 p.m. ET. The event will feature
Based in
Paragon 28, Inc. (NYSE: FNA) has launched its innovative Phantom® Metatarsal Shortening System, designed for in-line shortening osteotomies of the lesser metatarsals, which treat common foot ailments like metatarsalgia and floating toe. The system features a patent-pending cut guide for enhanced precision. CEO Albert DaCosta emphasized the system's potential to drive growth in the forefoot segment, complementing the company's existing portfolio, including TenoTac™ and HammerTube™. The launch aims to provide a comprehensive solution for surgeons addressing forefoot conditions.
Contributors to the design include renowned surgeons, underscoring the system's innovative approach to improving patient outcomes in foot and ankle orthopedic procedures.
Paragon 28, Inc. (NYSE: FNA), a prominent medical device company focusing on the foot and ankle orthopedic market, will announce its first quarter 2023 financial results on May 4, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET, providing insights into the company's financial performance and future outlook. Investors can join the call by dialing (833-470-1428) domestically or (929-526-1599) internationally, using conference ID: 007721. The event will also be webcasted live on the company's investor website, with a replay available for 90 days. Paragon 28 is dedicated to enhancing patient care through innovative orthopedic solutions for various foot and ankle conditions, aiming to improve surgical outcomes and reduce complications.
Paragon 28, Inc. (NYSE: FNA) reported its financial results for Q4 and full year 2022, showcasing a strong revenue performance.
Q4 consolidated net revenue reached $51.5 million, marking a 20.4% increase. For the full year, consolidated net revenue totaled $181.4 million, up 23%. U.S. revenue for Q4 was $45.3 million, contributing to a 22% annual growth rate. The gross margin remained robust at 82% for both Q4 and the entire year.
However, the company faced a net loss of $38.8 million for Q4, up from a loss of $6.2 million in the prior year, and an annual loss of $67.3 million.
Looking ahead, Paragon 28 anticipates net revenue of $214-$218 million for 2023, indicating an 18%-20% growth.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
